Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Regulation of CD1d expression and function by a herpesvirus infection
David Jesse Sanchez, Jenny E. Gumperz, Don Ganem
David Jesse Sanchez, Jenny E. Gumperz, Don Ganem
View: Text | PDF
Article Virology

Regulation of CD1d expression and function by a herpesvirus infection

  • Text
  • PDF
Abstract

Little is known about the role of CD1d-restricted T cells in antiviral immune responses. Here we show that the lytic replication cycle of the Kaposi sarcoma–associated herpesvirus (KSHV) promotes downregulation of cell-surface CD1d. This is caused by expression of the 2 modulator of immune recognition (MIR) proteins of the virus, each of which promotes the loss of surface CD1d expression following transfection into uninfected cells. Inhibition of CD1d surface expression is due to ubiquitination of the CD1d α-chain on a unique lysine residue in its cytoplasmic tail, which triggers endocytosis. Unlike MIR-mediated MHC class I downregulation, however, CD1d downregulation does not appear to include accelerated lysosomal degradation. MIR2-induced downregulation of CD1d results in reduced activation of CD1d-restricted T cells in vitro. KSHV modulation of CD1d expression represents a strategy for viral evasion of innate host immune responses and implicates CD1d-restricted T cells as regulators of this viral infection.

Authors

David Jesse Sanchez, Jenny E. Gumperz, Don Ganem

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
MIR2 downregulation of CD1d is due to endocytosis but not enhanced degra...
MIR2 downregulation of CD1d is due to endocytosis but not enhanced degradation. (A) BJAB cells were transiently transfected with wild-type chimeric CD1d. Both panels show the level of chimeric CD1d when cotransfected with wild-type dynamin (solid black lines) as well as the level of CD1d antibody background cross-reactivity (dotted black lines). The gray lines represent chimeric CD1d levels in the presence of MIR2 and either wild-type (left panel) or dominant-negative dynamin (K44E, right panel). (B) The half-life of CD1d in BJAB cells expressing lacZ or MIR2 was analyzed by pulse chase. As shown, the presence of the MIR2 gene does not change the half-life of the CD1d chains. Chloroquine (C) was added to block lysosomal degradation and showed no effect. (C) The half-life of CD1d in HepG2 cells expressing lacZ or MIR2 were analyzed by pulse chase. As shown, the presence of the MIR2 gene does not change the half-life of the CD1d chains (left blots), but does increase the levels of degradation of MHC class I (right blots). Addition of chloroquine stopped the MHC class I degradation. (D) Total cellular levels of proteins in BJAB cells that were stable for expression of MIR2 or lacZ was determined by flow cytometry. The presence of the MIR2 gene did not change the total levels of CD1d, even though the surface levels of CD1d were decreased. This is in contrast to the decreased total and surface levels of B7.2 and MHC class I.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts